Reprint
mTOR in Human Diseases
Edited by
June 2019
480 pages
- ISBN978-3-03921-060-2 (Paperback)
- ISBN978-3-03921-061-9 (PDF)
This book is a reprint of the Special Issue mTOR in Human Diseases that was published in
Biology & Life Sciences
Chemistry & Materials Science
Medicine & Pharmacology
Summary
The mechanistic target of rapamycin (mTOR) is a major signaling intermediary that coordinates favorable environmental conditions with cell growth. Indeed, as part of two functionally distinct protein complexes, named mTORC1 and mTORC2, mTOR regulates a variety of cellular processes, including protein, lipid, and nucleotide synthesis, as well as autophagy. Over the last two decades, major molecular advances have been made in mTOR signaling and have revealed the complexity of the events implicated in mTOR function and regulation. In parallel, the role of mTOR in diverse pathological conditions has also been identified, including in cancer, hamartoma, neurological, and metabolic diseases. Through a series of articles, this book focuses on the role played by mTOR in cellular processes, metabolism in particular, and highlights a panel of human diseases for which mTOR inhibition provides or might provide benefits. It also addresses future studies needed to further characterize the role of mTOR in selected disorders, which will help design novel therapeutic approaches. It is therefore intended for everyone who has an interest in mTOR biology and its application in human pathologies.
Format
- Paperback
License
© 2019 by the authors; CC BY-NC-ND license
Keywords
acute myeloid leukemia; metabolism; mTOR; PI3K; phosphorylation; epithelial to mesenchymal transition; mTOR inhibitor; pulmonary fibrosis; transcriptomics; miRNome; everolimus; mTOR; thyroid cancer; sodium iodide symporter (NIS)/SLC5A5; dopamine receptor; autophagy; AKT; mTOR; AMPK; mTOR; Medulloblastoma; MBSCs; mTOR; T-cell acute lymphoblastic leukemia; targeted therapy; combination therapy; mTOR; metabolic diseases; glucose and lipid metabolism; anesthesia; neurotoxicity; synapse; mTOR; neurodevelopment; mTOR; rapamycin; autophagy; protein aggregation; methamphetamine; schizophrenia; tumour cachexia; mTOR; signalling; metabolism; proteolysis; lipolysis; mTOR; mTORC1; mTORC2; rapamycin; rapalogues; rapalogs; mTOR inhibitors; senescence; ageing; aging; cancer; neurodegeneration; immunosenescence; senolytics; biomarkers; leukemia; cell signaling; metabolism; apoptosis; miRNA; mTOR inhibitors; mTOR; tumor microenvironment; angiogenesis; immunotherapy; fluid shear stress; melatonin; chloral hydrate; nocodazole; MC3T3-E1 cells; primary cilia; mTOR complex; metabolic reprogramming; cancer; microenvironment; nutrient sensor; oral cavity squamous cell carcinoma (OSCC); NVP-BEZ235; mTOR; p70S6K; mTOR; advanced biliary tract cancers; mTOR; NGS; illumina; IonTorrent; eIFs; mTOR; autophagy; Parkinson’s disease; mTOR; PI3K; cancer; inhibitor; therapy; mTOR; laminopathies; lamin A/C; Emery-Dreifuss muscular dystrophy (EDMD); Hutchinson-Gilford progeria syndrome (HGPS); autophagy; cellular signaling; metabolism; bone remodeling; ageing; mTOR; fructose; glucose; liver; lipid metabolism; gluconeogenesis; Alzheimer’s disease; autophagy; mTOR signal pathway; physical activity; microRNA; mTOR; spermatogenesis; male fertility; Sertoli cells; n/a